Skip to main content
. 2022 May 27;9:851782. doi: 10.3389/fmed.2022.851782

TABLE 1.

Blood parameters evaluated in the Mineral Metabolism and selected Blood Parameters (MMBP) study, Osteoporosis “Treatment of osteoporosis by Panaceo” (TOP) study, and Morbus Crohn study.

Clinical trial Measured standard blood parameters
MMBP study (NCT04607018)
Sample size: 15 volunteers (7 Naïve PMA users and 8 chronic PMA users) Na, K, Zn, Fe, Mg, and Ca mineral levels; AST; ALT; GGT; CREAT; GF evaluation; and contaminants panel measured by ICP-MS
Osteoporosis TOP study (NCT03901989)
Enrolled patients: 100 First study year comprised 50 patients in the placebo group and 50 patients in the verum group (PMA supplementation) CREAT, ALP, P, Ca, mineral and contaminants panel measured by ICP-MS
Morbus Crohn study (NCT04370535)
Enrolled patients: 30 comprising patients with uncontrolled Crohn disease + placebo (15 patients) and patients with uncontrolled Crohn disease + PMA (15 patients) Healthy volunteers: 10 control group + placebo (five test persons) and control group + PMA (five test persons) Sedimentation; blood count; Na, K, Cl, Fe, Mg, and Ca mineral levels; urea; CREAT; AST; ALT; GGT; bilirubin; CRP; procalcitonin; ferritin; calprotectin; and contaminants panel measured by ICP-MS

The sample size of each study is also presented (additional information are given in the Supplementary Material).

AST, Aspartate-aminotransferase; ALT, Alanine-aminotransferase; GGT, Gamma-glutamyltransferase; CREAT, Creatinine; ALP, Alkaline phosphatase; GF, Glomerular filtration; CRP, C-reactive protein.